Repare Therapeutics Inc. (RPTX)

Repare Therapeutics Inc. was a clinical-stage precision oncology company based in Montreal, Quebec, with operations in Cambridge, Massachusetts. It was founded in 2016 and built its approach around synthetic lethality, a concept in which the loss of two genes together kills a cell although the loss of either alone does not. The company used genome-wide CRISPR screening to identify tumor vulnerabilities and match them with targeted small molecules.

Its internal pipeline included lunresertib, an inhibitor of PKMYT1, and camonsertib, an inhibitor of ATR, both studied in solid tumors with specific genetic alterations. Repare also pursued other DNA damage response targets, such as a Polθ helicase inhibitor, and entered collaborations and licensing arrangements with other drug developers. Its work was concentrated in early- and mid-stage clinical trials.

Repare completed its initial public offering in June 2020 and listed its common shares on the Nasdaq Global Select Market under the symbol RPTX. As a Canadian company it was also a reporting issuer in Quebec. Like many clinical-stage biotechnology companies, it financed operations through equity offerings and partnership payments rather than product revenue.

In 2025 the company reassessed its strategy as it worked to preserve cash, and it explored strategic alternatives including a sale or other transaction. This process led to an agreement with XenoTherapeutics, Inc., a Massachusetts-based non-profit biotechnology organization focused on xenotransplantation. The arrangement was to be carried out under Canadian corporate law as a plan of arrangement.

Under the terms, shareholders received about US$2.20 in cash per common share, an amount calculated from Repare's cash balance just before closing after certain costs and liabilities, along with one non-transferable contingent value right per share. Shareholders approved the arrangement on January 16, 2026, and the Superior Court of Quebec issued its final order on January 23, 2026.

Repare announced completion of the acquisition on January 29, 2026, and said its common shares were expected to stop trading on Nasdaq on or about January 28, 2026. The company planned to file a Form 15 to deregister the shares and to cease being a reporting issuer in Quebec.

The transaction is an example of a reverse-style outcome for a clinical-stage biotechnology company with limited cash, in which holders received a payment tied mainly to the company's remaining cash balance plus the possibility of future payments through a contingent value right. The terms of the CVR depend on a separate agreement, and the amounts, if any, depend on future events described in that agreement. Following the closing, Repare's common shares no longer trade on Nasdaq, and the company planned to cease reporting obligations in both the United States and Quebec.